Effect of ANKASCIN 568-P Products Regulating Blood Lipid

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Hyperlipidemias

In brief

This study is a randomized, double-blind, placebo-controlled, parallel-controlled trial (24 weeks in total), divided into three periods (screening, treatment, and discontinuation follow-up)

Key facts

Study ID
NCT05737355
Run by
SunWay Biotech Co., LTD.
People needed
80
Starts
2023-04-01
Expected to finish
2025-10-31
Last updated by the study team
2025-08-28

Who can join

Age: 20 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.